Download PDF
Diabetes aktuell 2008; 6(1): 13-25
DOI: 10.1055/s-2008-1064937
Schwerpunkt

© Georg Thieme Verlag Stuttgart · New York

Pathophysiologie des Metabolisch-Vaskulären Syndroms - Abdominales Fettgewebe als äußeres Zeichen und wesentliche Triebkraft

Pathophysiology of the Metabolic Vascular Syndrome (MVS) - Abdominal Fatty Tissue as an External Sign and Essential Piloting ForceUlrich Julius1 , G. Scholz2
  • 1Medizinische Klinik und Poliklinik III, Universitätsklinikum Dresden
  • 2St. Elisabeth-Krankenhaus Leipzig, Abteilung Endokrinologie, Diabetologie,Kardiologie und Allgemeine Innere Medizin
Further Information

Publication History

Publication Date:
11 March 2008 (online)

Also available at
    Permissions and Reprints

Häufiges äußeres Zeichen und wesentliche Triebkraft eines Metabolisch-Vaskulären Syndroms (MVS) ist die Akkumulation von abdominalem Fettgewebe, das über eine Messung des Taillenumfangs grob erfasst und palpatorisch, zumindest orientierend, in das subkutane und das viszerale Kompartiment aufgeteilt werden kann. Durch Sonographie heute leicht erfassbar ist die charakteristische Leberverfettung, die u. a. für die erheblich eingeschränkte Wirkung des Insulins an der Leber eine entscheidende Rolle spielt. Dagegen ist die pathologische Fettansammlung im Muskelgewebe, speziell in den Myozyten, mit einfachen klinischen Verfahren nicht zu erkennen, sie kann aber bei massiver viszeraler Fettakkumulation und unzureichender körperlicher Aktivität per se angenommen werden.

Gegenüber der genetisch determinierten Insulinresistenz, die sicherlich eine gewisse Rolle bei der Manifestation des MVS und seiner Folgeschäden spielt, sind deshalb Formen der Insulinresistenz von größerer Bedeutung, die durch Fehlsteuerungen verschiedener Stoffwechselwege im Rahmen der viszeralen Fettakkumulation bei gleich bleibender Fehlernährung und reduzierter körperlicher Aktivität auftreten (lipotoxische Form der Insulinresistenz).

Accumulation of abdominal fatty tissue is a frequent external sign and essential piloting force promoting a metabolic vascular syndrome (MVS). Such an accumulation of fatty tisssue may be roughly detected by means of waist measurement. Palpation may separate this - at least for orientation - into subcutaneous and visceral fatty accumulation. The characteristic fatty degeneration of the liver is now easy to detect via sonography. This fatty degeneration is decisively responsible inter alia for the considerably reduced insulin activity at the liver. On the other hand, it is not so easy to identify the pathological fatty accumulation in the muscular tissue and especially in the myocytes if straightforward clinical methods are employed, but it can be assumed to be present in case of a massive visceral fatty accumulation and insufficient physical activity.

Without doubt a genetically determined insulin resistance is partly responsible for the manifestation of MVS and its resulting harmful effects, but for the reasons set out above it is most important to pay close attention to such kinds of insulin resistance which are due to a misdirection of various metabolic processes in respect of visceral fatty accumulation while nutritional errors persist and physical activity remains unsatisfactory (lipotoxic type of insulin resistance).

Key words

Metabolic Vascular Syndrome - abdominal fatty tissue - Waist measurement - insulin resistance

Literatur

  • 1 Ginsberg HN, Huang LS.. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis.  J Cardiovasc Risk. 2000;  7 325-331
    Google Scholar
  • 2 Julius U.. Influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia.  Exp Clin Endocrinol Diabetes. 2003;  111 246-250
    Article in Thieme ConnectGoogle Scholar
  • 3 Pietzsch J, Julius U, Kirch C, Fischer S, Hanefeld M.. Very low density lipoprotein overproduction is maximally expressed in early insulin resistant states.  Ann NY Acad Sci. 1999;  892 319-322
    Google Scholar
  • 4 McCarty F. M. A paradox resolved: the postprandial model of insulin resistance explains why gynoid adiposity appears to be protective.  Med Hypotheses. 2003;  61 73-76
    Google Scholar
  • 5 Boden G.. Die Rolle freier Fettsäuren in der Pathogenese von Insulinresistenz und Typ-II-Diabetes. In: Hanefeld M, Leonhardt W (ed). Das Metabolische Syndrom - ein integriertes Konzept zur Diagnostik und Therapie eines Clusters von Zivilisationskrankheiten. Gustav Fischer Verlag, Jena und Stuttgart 1996: 113-117
    Google Scholar
  • 6 Eckel RH, Grundy SM, Zimmet PZ.. The metabolic syndrome.  Lancet. 2005;  365 1415-1428
    CrossrefGoogle Scholar
  • 7 Björntorp P.. Obesity, insulin resistance and diabetes. In: Alberti KGMM, Krall LP (ed): The Diabetes Annual/6. Elsevier Science Publishers. London, Amsterdam. New York 1991: 347-370
    Google Scholar
  • 8 Bloomgarden ZT.. The 1st world congress on the insulin resistance syndrome.  Diab Care. 2004;  27 602-609
    CrossrefGoogle Scholar
  • 9 Schinner S, Scherbaum WA, Bornstein SR, Barthel A.. Molecular mechanisms of insulin resistance.  Diabet Med. 2005;  22 674-682
    CrossrefGoogle Scholar
  • 10 Krebs M, Roden M.. Nutrient-induced insulin resistance in human skeletal muscle.  Curr Med Chem. 2004;  11 901-908
    CrossrefGoogle Scholar
  • 11 Ilanni-Parikka P, Eriksson JG, Lindström J, Hämäläinen H. et al . Prevalence of the metabolic syndrome and its components - Findings from a Finnish general population sample and the Diabetes Prevention Study cohort.  Diab Care. 2004;  27 2135-2140
    CrossrefGoogle Scholar
  • 12 Müller-Wieland D, Kotzka J.. SREBP-1: gene regulatory key to syndrome X?.  Ann N Y Acad Sci. 2002;  967 19-27
    Google Scholar
  • 13 Brage S, Wedderkopp N, Ekelund U, Franks W P. et al. . Features of the metabolic syndrome are associated with objectively measured physical activity and fitness in Danish children.  Diab Care. 2004;  27 2141-2148
    CrossrefGoogle Scholar
  • 14 Laaksonen DE, Lakka HM, Salonen JT, Niskanen LK. et al. . Low levels of leisure-time physical activity and cardiorespiratory fitness predict development of the metabolic syndrome.  Diab Care. 2002;  25 1612-1618
    CrossrefGoogle Scholar
  • 15 Ekelund U, Brage S, Franks PW, Hennings S. et al. . Physical activity energy expenditure predicts progression toward the metabolic syndrome independently of aerobic fitness in middle-aged healthy caucasians.  Diab Care. 2005;  28 1195-1200
    CrossrefGoogle Scholar
  • 16 Thanopoulou AC, Karamanos BG, Angelico FV, Assaad-Khalil SH. et al. . Dietary fat intake as risk factor for the development of diabetes.  Diab Care. 2003;  26 302-307
    CrossrefGoogle Scholar
  • 17 Pankow S J, Jacobs R D, Steinberger J, Moran A, Sinaiko R A. Insulin resistance and cardiovascular disease risk factors in children of parents with the insulin resistance (metabolic) syndrome.  Diabetes Care. 2004;  27 775-780
    Google Scholar
  • 18 Maumus S, Marie B, Siest G, Visvikis-Siest S.. A prospective study on the prevalence of metabolic syndrome among healthy french families: two cardiovascular risk factors (HDL cholesterol and tumor necrosis factor-alpha) are revealed in the offspring of parents with metabolic syndrome.  Diab Care. 2005;  28 675-82
    CrossrefGoogle Scholar
  • 19 Bouchard C.. The biological predisposition to obesity: beyond the thrifty genotype scenario.  Int J Obes (London). 2007;  31 1337-1339
    CrossrefPubMedGoogle Scholar
  • 20 Nestel PJ.. Metabolic syndrome; multiple candidate genes, multiple environmental factors: multiple syndromes?.  Int J Clin Practice. 2003;  134 3-9
    Google Scholar
  • 21 Carr D, Utzschneider KM, Hull RL, Kodama K. et al. . Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome.  Diabetes. 2004;  53 2087-2094
    CrossrefGoogle Scholar
  • 22 Bloomgarden ZT.. Dyslipidemia and the metabolic syndrome.  Diab Care. 2004;  27 3009-3016
    CrossrefGoogle Scholar
  • 23 Björntorp P.. Abdominal obesity and the development of non-insulin-dependent diabetes mellitus.  Diab Metab Rev. 1988;  4 615-622
    Google Scholar
  • 24 Janssen I, Katzmarzyk PT, Ross R.. Waist circumference and not body mass index explains obesity-related health risk.  Am J Clin Nutr. 2004;  79 347-349
    Google Scholar
  • 25 Palaniappan L, Carnethon MR, Wang Y, Hanley AJG. et al. . Predictors of the incident metabolic syndrome in adults.  Diab Care. 2004;  27 788-793
    CrossrefGoogle Scholar
  • 26 Carnethon MR, Loria CM, Hill JO, Sidney S. et al. . Risk factores for the metabolic syndrome - The Coronary Artery Risk Development in Young Adults (CARDIA) study, 1985-2001.  Diab Care. 2004;  27 2707-2715
    CrossrefGoogle Scholar
  • 27 Freiberg MS, Cabral HJ, Heeren TC, Vasan RS, Ellison RC.. Alcohol consumption and the prevalence of the metabolic syndrome in the U.S. - A cross-sectional analysis of data from the Third National Health and Nutrition Examination Survey.  Diab Care. 2004;  27 2954-2959
    CrossrefGoogle Scholar
  • 28 Wyszynski DF, Waterworth DM, Barter PJ, Cohen J. et al. . Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project).  Am J Cardiol. 2005;  95 194-198
    CrossrefGoogle Scholar
  • 29 Pietzsch J, Julius U, Hanefeld M.. Metabolic basis of low high density lipoprotein in subjects with impaired glucose tolerance.  Ann NY Acad Sci. 1999;  892 323-326
    CrossrefGoogle Scholar
  • 30 Julius U, Kirschner E, Pietzsch J.. Intravasaler Lipidtransfer bei gestörter Glukosetoleranz (IGT): Beitrag zur Rolle des Cholesterolester-Transferproteins (CETP). In: Heinle H, Schulte H, Hahmann H (ed): Besondere Aspekte der cerebrovaskulären und peripheren Arteriosklerose. Deutsche Gesellschaft für Arterioskleroseforschung, Tübingen 2004: 50-54
    Google Scholar
  • 31 Holvoet P, Kritchevsky SB, Tracy RP, Mertens A. et al. . The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort.  Diabetes. 2004;  53 1068-1073
    CrossrefGoogle Scholar
  • 32 Holvoet P.. Oxidized LDL and coronary heart disease.  Acta Cardiol. 2004;  59 479-484
    CrossrefGoogle Scholar
  • 33 Hodge AM, English DR, O'Dea K, Giles GG.. Glycemic index and dietary fiber and the risk of type 2 diabetes.  Diab Care. 2004;  27 2701-2706
    Google Scholar
  • 34 Sattar N, Gaw A, Scherbakova O, Ford I. et al. . Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.  Circulation. 2003;  108 414-419
    CrossrefPubMedGoogle Scholar
  • 35 Hu FB, Manson JE, Stampfer MJ, Colditz G. et al. . Diet, lifestyle, and the risk of type 2 diabetes mellitus in women.  N Engl J Med. 2001;  345 790-797
    CrossrefPubMedGoogle Scholar
  • 36 Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K. et al. . Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men.  Diab Care. 2004;  27 1036-1041
    CrossrefGoogle Scholar
  • 37 D'Agostino Jr. RB, Hamman RF, Karter AJ, Mykkanen L. et al. . Cardiovascular disease risk factors predict the development of type 2 diabetes: the insulin resistance atherosclerosis study.  Diab Care. 2004;  27 2234-2240
    Google Scholar
  • 38 Dotevall A, Johansson S, Wilhelmsen L, Rosengren A.. Increased levels of triglycerides, BMI and blood pressure and low physical activity increase the risk of diabetes in Swedish women. A prospective 18-year follow-up of the BEDA study.  Diabet Med. 2004;  21 615-622
    CrossrefGoogle Scholar
  • 39 Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM.. The metabolic syndrome as predictor of type 2 diabetes - The San Antonio Heart Study.  Diab Care. 2003;  26 3153-3159
    CrossrefGoogle Scholar
  • 40 Stern MP, Williams K, González-Villalpando C, Hunt KJ, Haffner SM.. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?.  Diab Care. 2004;  27 2676-2681
    CrossrefGoogle Scholar
  • 41 Alvarez GE, Beske SD, Ballard TP, Davy KP.. Sympathetic neural activation in visceral obesity.  Circulation. 2002;  106 2533-2536
    CrossrefGoogle Scholar
  • 42 Philipp T.. Metabolisches Syndrom und Hypertonie. In: Hanefeld M, Leonhardt W (ed): Das Metabolische Syndrom - ein integriertes Konzept zur Diagnostik und Therapie eines Clusters von Zivilisationskrankheiten. Gustav Fischer Verlag, Jena Stuttgart 1996: 70-75
    Google Scholar
  • 43 Brunner EJ, Hemingway H, Walker BR, Page M. et al. . Adrenocortical, autonomic and inflammatory causes of the metabolic syndrome.  Circulation. 2002;  106 2659-2665
    CrossrefGoogle Scholar
  • 44 Ferrannini E, Natali A, Capaldo B, Lehtovirta M. et al. . Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity: European Group for the Study of Insulin Resistance (EGIR).  Hypertension. 1997;  30 1144-1149
    Google Scholar
  • 45 DeFronzo RA, Ferrannini E.. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease.  Diabetes Care. 1991;  14 173-194
    CrossrefGoogle Scholar
  • 46 Facchini FS, DoNascimento C, Reaven GM, Yip JW. et al. . Blood pressure, sodium intake, insulin resistance, and urinary nitrate excretion.  Hypertension. 1999;  33 1008-1012
    Google Scholar
  • 47 Engeli S, Schling P, Gorzelniak K, Boschmann M. et al. . The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?.  Int J Biochem Cell Biol. 2003;  35 807-825
    CrossrefGoogle Scholar
  • 48 Sharma AM.. Is there a rationale for angiotensin blockade in the management of obesity hypertension?.  Hypertension. 2004;  44 12-19
    CrossrefGoogle Scholar
  • 49 Ehrhart-Bornstein M, Arakelyan K, Krug AW, Scherbaum WA, Bornstein SR.. Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells.  Endocr Res. 2004;  30 865-870
    CrossrefPubMedGoogle Scholar
  • 50 Dieterle P, Bottermann P, Schwarz K.. Bedeutung der Hypertonie in der Pathogenese des Diabetes mellitus.  Verh Dtsch Ges Inn Med. 1968;  74 434-437
    Google Scholar
  • 51 Temelkova-Kurktschiev T, Koehler C, Henkel E, Hanefeld M.. Leukocyte count and fibrinogen are associated with carotid and femoral intima-media thickness in a risk population for diabetes.  Cardiovasc Res. 2002;  56 277-283
    CrossrefGoogle Scholar
  • 52 Ford ES.. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey.  Atherosclerosis. 2003;  168 351-358
    CrossrefGoogle Scholar
  • 53 Chen J, Wildman RP, Hamm LL, Muntner P. et al. . Association between inflammation and insulin resistance in U.S. nondiabetic adults - Results from the Third National Health and Nutrition Examination Survey.  Diab Care. 2004;  27 2960-2968
    CrossrefGoogle Scholar
  • 54 Duncan BB, Schmidt MI, Pankow JS, Ballantyne C. et al. . Atherosclerosis Risk in Communities Study. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study.  Diabetes. 2003;  52 1799-1805
    CrossrefGoogle Scholar
  • 55 Temelkova-Kurktschiev T, Siegert G, Bergmann S, Henkel E. et al. . Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes.  Metabolism. 2002;  51 743-749
    CrossrefGoogle Scholar
  • 56 Ridker PM, Hennekens CH, Buring JE, Rifai N.. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.  N Engl J Med. 2000;  342
    Google Scholar
  • 57 Hu FB, Meigs JB, Li TY, Rifai N, Manson E. J. Inflammatory markers and risk of developing type 2 diabetes in women.  Diabetes. 2004;  53 693-700
    CrossrefGoogle Scholar
  • 58 King DE, Mainous AG, Thomas A, Pearson W.. C-reactive protein and glycemic control in adults with diabetes.  Diab Care. 2003;  26 1535-1539
    Google Scholar
  • 59 Kaushal K, Heald AH, Siddals KW, Sandhu MS. et al. . The impact of abnormalities in IGF and inflammatory systems on the metabolic syndrome.  Diab Care. 2004;  27 2682-2688
    CrossrefGoogle Scholar
  • 60 Chandran M, Phillips SA, Ciaraldi T, Henry RR.. Adiponectin: More than just another fat cell hormone?.  Diab Care. 2003;  26 2442-2450
    CrossrefPubMedGoogle Scholar
  • 61 Maeda N, Shimomura I, Kishida K, Nishizawa H. et al. . Diet-induced insulin resistance in mice lacking adiponectin/ACRP30.  Nat Med. 2002;  8 731-737
    CrossrefPubMedGoogle Scholar
  • 62 Cnop M, Havel PJ, Utzschneider KM, Carr DB. et al. . Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex.  Diabetologia. 2003;  46 459-469
    Google Scholar
  • 63 Abbasi F, Chu JW, Lamendola C, McLaughlin T. et al. . Discrimination between obesity and insulin resistance in the relationship with adiponectin.  Diabetes. 2004;  53 585-590
    CrossrefGoogle Scholar
  • 64 Sierksma A, Patel H, Ouchi N, Kihara S. et al. . Effect of moderate alcohol consumption on adiponectin, tumor necrosis factor-alpha, and insulin sensitivity.  Diab Care. 2004;  27 184-189
    CrossrefGoogle Scholar
  • 65 Sonnenberg GE, Krakower GR, Kissebah AH.. A novel pathway to the manifestations of metabolic syndrome.  Obes Res. 2004;  12 180-186
    Google Scholar
  • 66 Schernthaner G.. Gestörte Hämostase bei Diabetes mellitus und Metabolischem Syndrom: Einflussfaktoren und potientielle Therapieinterventionen. In: Hanefeld M, Leonhardt W (ed): Das Metabolische Syndrom - ein integriertes Konzept zur Diagnostik und Therapie eines Clusters von Zivilisationskrankheiten. Gustav Fischer Verlag, Jena Stuttgart 1996: 138-161
    Google Scholar
  • 67 Godsland IF, Crook D, Proudler AJ, Stevenson JC.. Hemostatic risk factors and insulin sensitivity, regional body fat distribution, and the metabolic syndrome.  J Clin Endocrinol Metab. 2005;  90
    Google Scholar
  • 68 Tarkun I, Canturk Z, Arslan BC, Turemen E, Tarkun P.. The plasminogen activator system in young and lean women with polycystic ovary syndrome.  Endocr J. 2004;  51 467-472
    CrossrefGoogle Scholar
  • 69 Mavri A, Alessi MC, Juhan-Vague I.. Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases.  J Intern Med. 2004;  255 448-456
    CrossrefGoogle Scholar
  • 70 Hanefeld M, Fischer S, Julius U, Schulze J. et al. . Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up.  Diabetologia. 1966;  39 1577-1583
    Google Scholar
  • 71 Alexander CM, Landsman PB, Teutsch SM, Haffner SM.. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP).  Diabetes. 2003;  52 1210-1214
    CrossrefPubMedGoogle Scholar
  • 72 Malik S, Wong ND, Franklin S, Pio J, Fairchild C, Chen R.. Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein.  Diab Care. 2005;  28 690-693
    Google Scholar
  • 73 Bonora E, Formentini G, Calcaterra F, Lombardi S. et al. . HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects.  Diab Care. 2002;  25 1135-1141
    CrossrefGoogle Scholar
  • 74 Rewers M, Zaccaro D, D`Agostino R, Haffner S. et al. . Insulin sensitivity, insulinemia, and coronary artery disease - The Insulin Resistance Atherosclerosis Study.  Diab Care. 2004;  27 781-787
    CrossrefGoogle Scholar
  • 75 Ninomiya JK, L'Italien G, Criqui M, Whyte J. et al. . Association of the Metabolic Syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey.  Circulation. 2004;  109 42-46
    CrossrefGoogle Scholar
  • 76 Bonora E, Targher G, Formentini G, Calcaterra F. et al. . The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study.  Diabet Med. 2004;  21 52-58
    CrossrefGoogle Scholar
  • 77 Solymoss BC, Bourassa MG, Campeau L, Sniderman A. et al. . Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity.  Am J Cardiol. 2004;  93 159-164
    CrossrefGoogle Scholar
  • 78 Kip KE, Marroquin OC, Kelley DE, Johnson BD. et al. . Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study.  Circulation. 2004;  109 706-713
    CrossrefPubMedGoogle Scholar
  • 79 Isomaa B, Almgren P, Tuomi T, Forsen B. et al. . Cardiovascular morbidity and mortality associated with the metabolic syndrome.  Diab Care. 2001;  24 683-689
    CrossrefPubMedGoogle Scholar
  • 80 Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W. et al. . ostchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level.  Diab Care. 2000;  23 1830-1834
    CrossrefGoogle Scholar
  • 81 McNeill AM, Rosamond WD, Girman CJ, Golden SH. et al. . The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study.  Diab Care. 2005;  28 385-390
    CrossrefGoogle Scholar
  • 82 Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S. et al. . Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes - The Casale Monferrato Study.  Diab Care. 2004;  27 2689-2694
    CrossrefGoogle Scholar
  • 83 Meigs JB, Rutter MK, Sullivan LM, Fox CS. et al. . Impact of insulin resistance on risk of type 2 diabetes and cardiovasculardisease in people with metabolic syndrome.  Diab Care. 2007;  30 1219-1225
    CrossrefGoogle Scholar
  • 84 Anand SS, Yi Q, Gerstein H, Lonn E. et al. . Study of Health Assessment and Risk in Ethnic Groups, Study of Health Assessment and Risk Evaluation in Aboriginal Peoples Investigators: Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease.  Circulation. 2003;  108 420-425
    CrossrefGoogle Scholar
  • 85 Al J Suwaidi, Higano S, Holmes DJ, Lennon R, Lerman A.. Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries.  J Am Coll Cardiol. 2001;  37 1523-1528
    CrossrefGoogle Scholar
  • 86 Steinberg HO, Chaker H, Leaming R, Johnson A. et al. . Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance.  J Clin Invest. 1996;  97 2601-2610
    CrossrefGoogle Scholar
  • 87 Vehkavaara S, Seppälä-Lindroos A, Westerbacka J, Groop PH, Yki-Järvinen H.. In vivo endothelial dysfunction characterizes patients with impaired fasting glucose.  Diab Care. 1999;  22 2055-2060
    Google Scholar
  • 88 Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB. et al. . Non-alcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.  Gastroenterology. 2001;  120 1183-1192
    CrossrefGoogle Scholar
  • 89 Björntorp P.. Neuroendokrine Anomalien beim Metabolischen Syndrom. In: Hanefeld M, Leonhardt W (ed): Das Metabolische Syndrom - ein integriertes Konzept zur Diagnostik und Therapie eines Clusters von Zivilisationskrankheiten. Gustav Fischer Verlag, Jena Stuttgart 1996: 53-61
    Google Scholar
  • 90 Andrew R, Westerbacka J, Wahren J, Yki-Järvinen H, Walker R. B. The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans.  Diabetes. 2005;  54 1364-1370
    CrossrefGoogle Scholar
  • 91 Muller M, Grobbee DE, den I Tonkelaar, Lamberts SW, van de YT. Schouw. Endogenous sex hormones and metabolic syndrome in aging men.  J Clin Endocrinol Metab. 2005;  90 2618-2623
    CrossrefPubMedGoogle Scholar
  • 92 Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K. et al. . The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study.  J Clin Endocrinol Metab. 2005;  90 712-719
    CrossrefGoogle Scholar
  • 93 Mor E, Zograbyan A, Saadat P, Bayrak A. et al. . The insulin resistant subphenotype of polycystic ovary syndrome: clinical parameters and pathogenesis.  Am J Obstet Gynecol. 2004;  190 1654-1660
    CrossrefGoogle Scholar
  • 94 Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K. et al. . Sex hormones, inflammation and the metabolic syndrome: a population-based study.  Eur J Endocrinol. 2003;  49 601-608
    Google Scholar
  • 95 Tsai EC, Matsumoto AM, Fujimoto WY, Boyko EJ.. Association of bioavailable, free, and total testo-sterone with insulin resistance: influence of sex hormone-binding globulin and body fat.  Diab Care. 2004;  27 861-868
    CrossrefGoogle Scholar
  • 96 Abate N, Haffner SM, Garg A, Peshock RM, Grundy SM.. Sex steroid hormones, upper body obesity, and insulin resistance.  J Clin Endocrinol Metab. 2002;  87 4522-4527
    CrossrefGoogle Scholar
  • 97 Lee CC, Kasa-Vubu JZ, Supiano MA.. Androgenicity and obesity are independently associated with insulin sensitivity in postmenopausal women.  Metabolism. 2004;  53 507-512
    CrossrefGoogle Scholar
  • 98 Kalish GM, Barrett-Connor E, Laughlin GA, Gulanski BI.. Association of endogenous sex hormones and insulin resistance among postmenopausal women: results from the Postmenopausal Estrogen/Progestin Intervention Trial.  J Clin Endocrinol Metab. 2003;  88 1646-1652
    CrossrefGoogle Scholar
  • 99 Golden SH, Ding J, Szklo M, Schmidt MI. et al. . Glucose and insulin components of the metabolic syndrome are associated with hyperandrogenism in postmenopausal women: the atherosclerosis risk in communities study.  Am J Epidemiol. 2004;  160 540-548
    CrossrefGoogle Scholar
  • 100 Apridonidze T, Essah PA, Iuorno MJ, Nestler JE.. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2005;  90 1929-1935
    CrossrefPubMedGoogle Scholar
  • 101 Buffington CK, Kitabchi AE.. Evidence for a defect in insulin metabolism in hyperandrogenic women with polycystic ovarian syndrome.  Metabolism. 1994;  43 1367-1372
    CrossrefGoogle Scholar
  • 102 Coughlin SR, Mawdsley L, Mugarza JA, Calverley PM, Wilding JP.. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome.  Eur Heart J. 2004;  25 735-741
    CrossrefGoogle Scholar

Korrespondenz

Prof. Dr. Julius Ulrich

Medizinische Klinik und Poliklinik III Universitätsklinikum

Fetscherstraße 74

01307 Dresden

Phone: 0351/458-2306

Fax: 0351/458-5306

Email: julius@rcs.urz.tu-dresden.de